VERTEX PHARMACEUTICALS INC / MA (VRTX) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 34 days, typically, give or take 4 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 2, 2026after close 33 8-K
Q2 FY2026Mon, Aug 3, 2026after close 34 8-K
Q1 FY2026Mon, May 4, 2026after close 34 8-K
Q4 FY2025Thu, Feb 12, 2026after close 43 8-K
Q3 FY2025Mon, Nov 3, 2025after close 34 8-K
Q2 FY2025Mon, Aug 4, 2025after close 35 8-K
Q1 FY2025Mon, May 5, 2025after close 35 8-K
Q4 FY2024Mon, Feb 10, 2025after close 41 8-K

What they guided beta

Q3 FY2026 "Document Vertex Reports Third Quarter 2026 Financial Results — Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 — — Raising full-year revenue guidance to $13.15 billion to $13.25 billion — — Established fourth commercial pillar in rare endocrine diseases with closing of Crinetics Pharmaceuticals acquisition and preparing for fifth in renal medicine with povetacicept PDUFA date on November 30 th — — R&D pipeline continues to advance with multiple additional near-term milestones — BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported c" exhibit
Q3 FY2026 "Non-GAAP net income was $1.2 billion in each of the third quarters of 2026 and 2025, as increased product revenue was of fset by increased operating expenses to fund pipeline and commercial opportunities, as well as higher interest expense and lower interest income as a result of the Crinetics Pharmaceuticals acquisition." exhibit
Q3 FY2026 "Cash, cash equivalents, and total marketable securities as of September 30, 2026, were $9.8 billion, compared to $12.3 billion as of December 31, 2025, primarily due to $9.0 billion net cash used to acquire Crinetics Pharmaceuticals and to repurchase Vertex common stock pursuant to its share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan executed in the third quarter of 2026 and cash flows provided by Vertex’s operating activities. 2 Full Year 2026 Financial Guidance Vertex today raised its full year 2026 total revenue guidance to $13.15 billion to $13.25" exhibit
Q3 FY2026 "Vertex is also increasing full year 2026 combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expense guidance to reflect expenses primarily related to the operations and integration of Crinetics Pharmaceuticals for the remainder of 2026." exhibit
Q3 FY2026 "Vertex’s financial guidance is summarized below: Current FY 2026 Previous FY 2026 Total revenue $13.15 to $13.25 billion $13.1 to $13.2 billion Legacy non-CF product revenue (CASGEVY, JOURNAVX) Unchanged $0.5 billion or greater PALSONIFY revenue $40 to $50 million Combined GAAP R&D, AIPR&D, and SG&A expenses * $7.15 to $7.2 billion $6.3 to $6.45 billion Combined non-GAAP R&D, AIPR&D, and SG&A expenses* Approximately $6.0 billion $5.65 to $5.75 billion Non-GAAP effective tax rate Unchanged 19.5% to 20.5% *The difference between the combined GAAP R&D, AIPR&D and SG&A expenses and the combined no" exhibit
Q2 FY2026 "Document Vertex Reports Second Quarter 2026 Financial Results — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026 — BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and upda" exhibit
Q2 FY2026 "Full Year 2026 Financial Guidance Vertex today raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously." exhibit
Q2 FY2026 "Vertex reiterated its full year 2026 guidance for combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses of $6.3 billion to $6.45 billion and $5.65 billion to $5.75 billion, respectively." exhibit
Q2 FY2026 "This guidance also continues to include an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations." exhibit
Q2 FY2026 "Vertex’s financial guidance for 2026 does not reflect the impact of the pending acquisition of Crinetics Pharmaceuticals." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VRTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VRTX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

VRTX earnings date badge

HTML

<a href="https://veritasdata.dev/company/VRTX/"><img src="https://veritasdata.dev/embed/VRTX.svg" alt="VRTX earnings date" width="240" height="56"></a>

Markdown

[![VRTX earnings date](https://veritasdata.dev/embed/VRTX.svg)](https://veritasdata.dev/company/VRTX/)

Script

<script async src="https://veritasdata.dev/embed/VRTX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VRTX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.